Milestone Scientific Inc. (MLSS)
| Market Cap | 39.40M -14.9% |
| Revenue (ttm) | 9.42M +3.7% |
| Net Income | -4.14M |
| EPS | -0.05 |
| Shares Out | 88.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,790 |
| Open | 0.4425 |
| Previous Close | 0.4341 |
| Day's Range | 0.4282 - 0.4450 |
| 52-Week Range | 0.2181 - 0.6000 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 1.25 (+181.53%) |
| Earnings Date | Aug 13, 2026 |
About MLSS
Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides The Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery sys... [Read more]
Financial Performance
In 2025, Milestone Scientific's revenue was $8.97 million, an increase of 3.99% compared to the previous year's $8.63 million. Losses were -$5.72 million, 21.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MLSS stock is "Buy." The 12-month stock price target is $1.25, which is an increase of 181.53% from the latest price.
News
Milestone Scientific files $45M mixed securities shelf
17:20 EDT Milestone Scientific (MLSS) files $45M mixed securities shelf
Milestone Scientific Registration statement: Registration filing
Milestone Scientific filed a registration statement on September 8, 2026, providing details about a securities offering with the SEC.
Milestone Scientific Earnings Call Transcript: Q2 2026
Q2 2026 revenue rose 22% year-over-year to $2.8M, driven by strong Medical segment growth and international Dental orders. Gross margin declined due to product mix and tariffs, but net loss narrowed. Guidance for 2026 was reaffirmed, with Q3 expected to be seasonally lower.
Milestone Scientific Quarterly report: Q2 2026
Milestone Scientific has published its Q2 2026 quarterly earnings report on August 14, 2026.
Milestone Scientific Earnings release: Q2 2026
Milestone Scientific released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Milestone Scientific Reports Financial Results for Second Quarter 2026
Medical Segment Revenue Grows 231% Year-Over-Year Enters Strategic Distribution Agreement to Expand CompuFlo® Access Across VA and Department of Defense Health Systems Reaffirms 2026 Outlook for Doubl...
Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call
ROSELAND, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, to...
Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System
Partnership Expands Commercial Reach Across VA, Department of Defense and Other Federal Healthcare Systems Partnership Expands Commercial Reach Across VA, Department of Defense and Other Federal Healt...
Milestone Scientific Transcript: AGM 2026
The meeting approved all proposals, including director elections, increased authorized shares, and expanded the equity incentive plan. Leadership emphasized operational discipline, growth, and alignment of executive incentives with performance milestones.
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
AI-powered Initiative Aims to Enhance Customer Engagement, Accelerate Commercial Execution and Support Long-Term Growth
Milestone Scientific reports preliminary Q2 revenue $2.8M, two estimates $2.5M
Revenue was driven by base business performance contributing approximately $2.4M, which was bolstered by approximately $500,000 in upside from international orders and 300% revenue growth in the medic...
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
Medical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025 Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Boar...
Milestone Scientific Strengthens Board to Support Next Phase of Growth
ROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, to...
Milestone Scientific Proxy statement: Proxy filing
Milestone Scientific filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.
Milestone Scientific Proxy statement: Proxy filing
Milestone Scientific filed a proxy statement on June 10, 2026, providing details for shareholder voting and corporate governance matters.
Milestone Scientific Proxy statement: Proxy filing
Milestone Scientific filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Milestone Scientific registers to sell 7.96M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 7.96M shares of common stock. The company is not selling any…
Milestone Scientific Registration statement: Registration filing
Milestone Scientific filed a registration statement on June 2, 2026, providing details about a securities offering with the SEC.
Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures
ROSELAND, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments utilizing Dynamic Pressure Sensing™ (DPS...
Milestone Scientific Earnings Call Transcript: Q1 2026
Revenue and gross profit remained stable, with significant cost reductions narrowing net loss by 58%. Medical segment revenue more than doubled, driven by CompuFlo adoption and digital marketing, while new financing supports growth and international expansion.
Milestone Scientific Quarterly report: Q1 2026
Milestone Scientific has published its Q1 2026 quarterly earnings report on May 14, 2026.
Milestone Scientific Earnings release: Q1 2026
Milestone Scientific released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Milestone Scientific reports Q1 EPS (1c), consensus (1c)
Reports Q1 revenue $2.16M, consensus $2.5M. “Our first quarter results reflect continued progress as we execute on the foundation established in 2025,” said Eric Hines, CEO of Milestone Scientific (ML...
Milestone Scientific backs FY26 revenue view $9.8M-$10.2M, consensus $9.91M
The company said, “Management reaffirms its outlook for the year ending December 31, 2026, with expected revenue of $9.8 million to $10.2 million, representing double-digit growth driven by expanding ...
Milestone Scientific Reports Financial Results for First Quarter 2026
Operating Loss Reduced As Company Advances Toward Profitability Reaffirms Outlook for Double-Digit Revenue Growth in 2026, including Significant Growth in CompuFlo® Sales ROSELAND, N.J., May 14, 2026 ...